Wendy Holman, CEO

Wendy Holman is the CEO and co-founder of Ridgeback Biotherapeutics.

Ms. Holman is passionate about global health and equality, education and advocating for diseases and patients who need champions. She is extraordinarily proud to lead the Ridgeback team for EBANGA™ which received FDA approval in 2020 for the treatment of Ebola. Ridgeback’s focus on emerging infectious disease led Ms. Holman and her team to invest behind and support development of antivirals for coronaviruses, as well as other new pathogens.

Prior to co-founding Ridgeback, Ms. Holman worked at US-based ZBI Equities, a multi-billion dollar public equity investment fund and its parent company, Ziff Brothers Investments. Between 1999 and 2014, she held various positions including healthcare sector head and director of research at ZBI Equities, and Principal at Ziff Brothers Investments. Ms. Holman’s investment focus was on novel and emerging technologies and platforms which could have a significant impact on human health.

Wendy serves on a variety of non-profit boards. She is a trustee for the University of Pennsylvania and the Ransom Everglades School. She is a member of the Board of Advisors for the University of Pennsylvania Libraries, and Penn Medicine’s Council for Discovery Science. Wendy also previously served on the board of the Sabin Vaccine Institute’s research and development committee.

Interests: FAMILY and FRIENDS! I am a forever learner who enjoys reading, great conversations and new discoveries — even better if that in some way includes, my kids, my husband or my dogs.

“My true addiction in life is learning and immersing myself in projects with great people and humanitarian missions.”